Daniel F Darvish

20120276560, Nov 1, 2012

Dec 16, 2011

13/329036

Emil D. Kakkis - Novato CA, US
Daniel K. Darvish - Reseda CA, US

G01N 33/566
G01N 33/577

435 792

The present invention relates to methods of diagnosing, monitoring and assessing conditions of sialic acid deficiency such as Hereditary Inclusion Body Myopathy (HIBM) and to methods of predicting/determining responsiveness to treatment.

20130030040, Jan 31, 2013

Feb 1, 2012

13/364181

Daniel DARVISH - Sherman Oaks CA, US

HIBM RESEARCH GROUP, INC. - Reseda CA

A61K 48/00
A61M 5/31
A61P 21/00
C12N 15/63
C12N 9/90

514 44 R, 4353201, 435194, 604506

Disclosed herein are methods of expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) peptide in a cell of a subject comprising: delivering into the cell of the subject an isolated nucleic acid expression construct that comprises a promoter operatively linked to a nucleic acid sequence encoding a GNE peptide or a therapeutically active fragment thereof, wherein the GNE peptide has the amino acid sequence of SEQ ID NO:3, wherein upon the delivering into the cell of the subject, the nucleic acid expression construct initiates expression of the GNE peptide or a therapeutically active fragment thereof. Also disclosed are methods of producing a GNE peptide in a cell comprising infecting the cell with an isolated nucleic acid construct that comprises a promoter operatively linked to a nucleic acid sequence encoding a GNE peptide or a therapeutically active fragment thereof, wherein the GNE peptide has the amino acid sequence of SEQ ID NO:3.

20090298112, Dec 3, 2009

May 28, 2008

12/128517

Daniel Kohan Darvish - Sherman Oaks CA, US

HIBM RESEARCH GROUP, INC. - Encino CA

C12Q 1/02
C12N 15/00
C12N 5/06
A01K 67/027

435 29, 4353201, 435352, 800 13

Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof, and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed.

20210100879, Apr 8, 2021

Sep 18, 2019

16/574644

Daniel Darvish - Los Angeles CA, US

A61K 38/47
C12N 15/86
C12N 7/00
A61K 9/00
C12N 9/24
C12N 9/12
A61K 45/06
A61K 38/45
A61P 21/04

The invention relates to composition and methods for expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) in a living organism. In preferred embodiments, the invention relates to treating disease condition that involves use of therapeutically effective amount of a composition described herein.

20200239054, Jul 30, 2020

Jan 17, 2019

16/250567

Daniel Darvish - Chatsworth CA, US

B62B 3/02

A foldable cart includes a handle portion, a foldable frame movably connected to the handle, and one or more wheels for rolling on a surface. In an unfolded (in-use or open) condition, the foldable frame constructs a holding-space defining a receiving cavity therein for carrying items, and the action of unfolding the frame automatically deploys wheels to enable immediate use of the cart by the end-user or customer. In a folded (storage or closed) condition, the carts' frame folds to occupy a smaller space in one or more spatial dimensions, and the automatically deployed wheels turn to occupy smaller total space in one or more spatial dimensions. In the folded condition, the cart is easy to store in a small space (e.g. in a small closet, under a bed, etc.) or transport (e.g. in the trunk of an automobile, vehicle, airplane, train, ship with a courier, etc.).

20190374652, Dec 12, 2019

Jun 12, 2018

16/006767

Daniel Darvish - Los Angeles CA, US

A61K 48/00
C12N 15/52
C12N 15/85
A61P 21/00

Disclosed herein are methods of expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) peptide in a cell of a subject comprising: delivering into the cell of the subject an isolated nucleic acid expression construct that comprises a promoter operatively linked to a nucleic acid sequence encoding a GNE peptide or a therapeutically active fragment thereof, wherein the GNE peptide has the amino acid sequence of SEQ ID NO:3, wherein upon the delivering into the cell of the subject, the nucleic acid expression construct initiates expression of the GNE peptide or a therapeutically active fragment thereof. Also disclosed are methods of producing a GNE peptide in a cell comprising infecting the cell with an isolated nucleic acid construct that comprises a promoter operatively linked to a nucleic acid sequence encoding a GNE peptide or a therapeutically active fragment thereof, wherein the GNE peptide has the amino acid sequence of SEQ ID NO:3.

20190083516, Mar 21, 2019

Nov 18, 2015

15/527470

- Mexico D.F., MX
Daniel DARVISH - Chatsworth CA, US
Carlos Asdrubal VALLES ORTIZ - Mexico, D.F., MX
Sergio Jaime ARIAS ZEPEDA - Jalisco, MX

VENTRINE S. DE R.L. DE C.V. - Mexico D.F.

A61K 31/7012
A61K 31/702
A61K 31/7004
A61K 33/06
A61K 9/16
A23L 33/10

The instant invention relates to a composition useful as a nutritional supplement comprising acetylated neuraminate (NeuAc), and/or a compound selected from N-acetyl mannosamine (ManNac), at least one or more compounds of the NeuAc biosynthetic pathway, substrates, products, or derivative thereof, or a mixture thereof; and a divalent metal ion. The composition of the invention permits to increase serum and or cellular NeuAc content in a subject.